T1	Participants 67 96	patients with type 2 diabetes
T2	Participants 164 188	type 2 diabetic patients
T3	Participants 602 695	50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (≥80-<600 μg)
T4	Participants 773 788	treatment group
T5	Participants 940 953	control group
T6	Participants 1396 1433	Chinese patients with type 2 diabetes
T7	Participants 1470 1498	treatment and control groups
T8	Participants 1662 1675	control group
T9	Participants 1839 1854	treatment group
T10	Participants 1931 1944	control group
T11	Participants 1946 1977	17 (68%) control-group patients
T12	Participants 1982 2014	9 (36%) treatment-group patients
T13	Participants 2205 2229	type 2 diabetic patients
